LGVN vs. PHAS, PHIO, BCEL, NBY, GOVX, REVB, ARDS, EVOK, ZVSA, and SEEL
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include PhaseBio Pharmaceuticals (PHAS), Phio Pharmaceuticals (PHIO), Atreca (BCEL), NovaBay Pharmaceuticals (NBY), GeoVax Labs (GOVX), Revelation Biosciences (REVB), Aridis Pharmaceuticals (ARDS), Evoke Pharma (EVOK), ZyVersa Therapeutics (ZVSA), and Seelos Therapeutics (SEEL). These companies are all part of the "pharmaceutical preparations" industry.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
PhaseBio Pharmaceuticals received 110 more outperform votes than Longeveron when rated by MarketBeat users. However, 88.89% of users gave Longeveron an outperform vote while only 61.78% of users gave PhaseBio Pharmaceuticals an outperform vote.
In the previous week, Longeveron had 5 more articles in the media than PhaseBio Pharmaceuticals. MarketBeat recorded 6 mentions for Longeveron and 1 mentions for PhaseBio Pharmaceuticals. PhaseBio Pharmaceuticals' average media sentiment score of 0.67 beat Longeveron's score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.
Longeveron has a consensus price target of $12.00, suggesting a potential upside of 837.50%.
Longeveron has lower revenue, but higher earnings than PhaseBio Pharmaceuticals. Longeveron is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
PhaseBio Pharmaceuticals has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
49.0% of PhaseBio Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are owned by company insiders. Comparatively, 24.3% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Longeveron has a net margin of -2,129.24% compared to Longeveron's net margin of -12,572.13%. Longeveron's return on equity of 0.00% beat PhaseBio Pharmaceuticals' return on equity.
Summary
Longeveron beats PhaseBio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
